Lonza will manufacture BNC101 at Slough facility in the UK.
Bionomics CEO and managing director Dr Deborah Rathjen said, "The start of manufacturing activities for BNC101 signals a significant step towards clinical trials. We anticipate that Bionomics will commence clinical trials of BNC101 in 2014."
Various preclinical studies revealed that BNC101 is functional active against high value cancer stem cell receptor LGR5.
Animal studies involving primary colorectal cancer patient samples with multiple underlying gene mutations revealed that BNC101 reduces cancer stem cell frequency and prevents tumor re-growth.